While abdominal ultrasound is recommended in all guidelines, usage of serum AFP as a tumor biomarker remains controversial due to low sensitivity and suboptimal cost-effectiveness in the detection of early-stage HCC [3]. This evidence concerns the gene AFP and hepatocellular carcinoma.